LOS ANGELES, April 24, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its first quarter 2025 financial results on Monday, May 12, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International ...

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Executive Officer, will be presenting virtually at the 35th Oppenheimer Healthcare MedTech & Services Conference on Monday, March 17, 2025 at 12:40 p.m. Eastern Time. A live webcast of RadNet's presentati ...

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Executive Officer, will be presenting virtually at the 35th Oppenheimer Healthcare MedTech & Services Conference on Monday, March 17, 2025 at 12:40 p.m. Eastern Time. A live webcast of RadNet's presentat ...

Financial Performance - Total Company Revenue for Q4 2024 reached a record $477.1 million, up 13.5% from $420.4 million in Q4 2023[4] - Adjusted EBITDA for Q4 2024 was $75.0 million, representing a 14.0% increase from $65.8 million in Q4 2023[4] - For full-year 2024, Total Company Revenue was $1,829.7 million, a 13.2% increase, and Adjusted EBITDA was $279.5 million, up 20.3%[11] - Net income attributable to RadNet, Inc. common stockholders for 2024 was $2,793, compared to $3,044 in 2023, reflecting a decrease of 8.2%[37] - Net income attributable to Radnet, Inc. common stockholders for Q4 2024 was $5,345, compared to a net loss of $1,860 in Q4 2023, representing a significant turnaround[42] - Adjusted EBITDA for Q4 2024 was $75,008, compared to $65,813 in Q4 2023, reflecting a growth of 13.3%[43] - Adjusted diluted net income per share attributable to Radnet, Inc. common stockholders for Q4 2024 was $0.22, up from $0.15 in Q4 2023[45] Revenue Segments - Digital Health Revenue increased 28.1% to $18.9 million in Q4 2024, with Adjusted EBITDA rising 61.6% to $4.5 million[7] - Total service revenue for 2024 reached $1,829,664, an increase of 13.2% from $1,616,630 in 2023[37] - Digital Health segment revenue guidance for 2025 is set between $80 million and $90 million, with Adjusted EBITDA before non-capitalized R&D projected at $15 million to $17 million[24] Cash and Debt Management - The cash balance at year-end 2024 was $740 million, with a net debt to Adjusted EBITDA leverage ratio below 1.0x, down from approximately 2.0x at year-end 2023[5] - Cash and cash equivalents increased to $740,020 in 2024 from $342,570 in 2023, representing a growth of 116.5%[35] - Cash paid for interest during the year was $84,601, up from $64,695 in 2023, indicating increased financing costs[39] - Net cash provided by operating activities for the year ended December 31, 2024 was $233,023, an increase from $220,863 in 2023[39] Operational Metrics - Aggregate procedural volumes grew by 8.0% and same-center procedural volumes increased by 4.0% compared to Q4 2023[4] - Total procedures for Q4 2024 reached 2,771,753, up from 2,565,720 in Q4 2023, marking an increase of 8.0%[51] - MRI procedures increased to 452,063 in Q4 2024 from 398,625 in Q4 2023, reflecting a growth of 13.4%[51] Future Guidance and Investments - 2025 guidance for Total Net Revenue is projected between $1,825 million and $1,875 million, with Adjusted EBITDA expected to be between $265 million and $273 million[22] - The company plans to implement new Digital Health solutions in 2025 to enhance operational efficiencies and address labor challenges[20] - Significant infrastructure investments will be made in 2025 to support sales, marketing, and implementation teams for Digital Health solutions[20] Assets and Liabilities - Total assets grew to $3,286,690 in 2024, up from $2,690,473 in 2023, marking an increase of 22.1%[35] - Long-term operating lease liabilities increased to $655,979 in 2024 from $605,097 in 2023, reflecting an increase of 8.4%[35] - RadNet's goodwill increased to $710,663 in 2024 from $679,463 in 2023, showing a rise of 4.6%[35] Miscellaneous - The company operates a network of 398 outpatient imaging centers across multiple states, employing over 11,000 individuals[27] - The company incurred severance costs of $1,105 in Q4 2024, compared to $621 in Q4 2023, indicating ongoing restructuring efforts[42] - The company reported a loss of $9,926 from equity in earnings of joint ventures in 2024, contrasting with a gain of $9,176 in 2023[39] - The restated Adjusted Earnings for 2023 include a loss of $4,973 from AI businesses, which is now part of the Digital Health segment[47] - The company anticipates continued impacts from COVID-19 on its business results and liquidity moving forward[28] - The company emphasizes that Adjusted EBITDA and Free Cash Flow should not be considered measures of financial performance under GAAP[55]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the transition period from to Commission file number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3326724 (State or other jurisdiction of incorporation or organizat ...

RadNet, Inc. (NASDAQ:RDNT) Q4 2024 Earnings Conference Call February 28, 2025 10:30 AM ET Company Participants Mark Stolper - Executive Vice President & Chief Financial Officer Howard Berger - President & Chief Executive Officer Conference Call Participants David MacDonald - Truist Brian Tanquilut - Jefferies John Ransom - Raymond James Andrew Mok - Barclays Larry Solow - CJS Securities Jim Sidoti - Sidoti & Company Operator Good day, and welcome to the RadNet, Inc. Fourth Quarter 2024 Financial Results Con ...

RadNet (RDNT) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 46.67%. A quarter ago, it was expected that this operator of medical diagnostic imaging centers would post earnings of $0.15 per share when it actually produced earnings of $0.18, delivering a surprise of 20%.Over the last ...

Core Insights - RadNet, Inc. reported strong financial performance for Q4 and full-year 2024, with revenue increasing by 13.5% to $477.1 million and Adjusted EBITDA rising by 14.0% to $75.0 million compared to Q4 2023 [2][4][5] - The company experienced an 8.0% growth in aggregate procedural volumes and a 4.0% increase in same-center procedural volumes during Q4 2024 [4][9] - Digital Health revenue reached $18.9 million in Q4 2024, marking a 28.1% increase from the previous year, and Adjusted EBITDA for this segment surged by 61.6% [5][11] Financial Performance - For the full year 2024, RadNet reported total revenue of $1,829.7 million, a 13.2% increase from 2023, and Adjusted EBITDA of $279.5 million, up 20.3% [10] - The cash balance at the end of 2024 was $740 million, significantly up from $342 million at the end of 2023, and the net debt to Adjusted EBITDA ratio improved to below 1.0x from approximately 2.0x [3][4] Digital Health Division - The Digital Health segment generated $65.7 million in revenue for the full year 2024, a 32.5% increase, with Adjusted EBITDA rising by 124.0% to $14.6 million [11] - New solutions such as DeepHealth OS and SmartMammo were launched in Q4 2024, aimed at enhancing operational efficiencies and addressing labor shortages [2][24] Operational Expansion - RadNet opened nine new imaging centers in 2024, increasing the total number of locations to 398, with joint venture facilities now representing 38.4% of these locations [2][4] - The company plans to implement new Digital Health solutions across its network in 2025 to further streamline operations and improve patient experience [2][24] 2025 Guidance - For 2025, RadNet anticipates total net revenue in the range of $1,825 to $1,875 million and Adjusted EBITDA between $265 to $273 million [19] - The company expects to face challenges due to severe weather conditions and other unforeseen events impacting healthcare service utilization, estimating a loss of $22 million in revenue and $15 million in Adjusted EBITDA for Q1 2025 [18][24]

Core Insights - RadNet, Inc. has partnered with OB/GYN Specialists of the Palm Beaches to launch breast imaging services across multiple locations in Palm Beach County, utilizing advanced technologies from RadNet and its subsidiary DeepHealth [1][2] - The collaboration aims to enhance early detection of breast cancer through on-site mammography and AI-driven diagnostic solutions, improving patient outcomes [2][3] Company Overview - RadNet, Inc. is a leading national provider of outpatient diagnostic imaging services, operating 399 imaging centers across various states in the U.S. [7][8] - OB/GYN Specialists is the largest provider of obstetric and gynecological care in Palm Beach County, serving nearly 60,000 women annually across 10 locations [2] Technology and Services - The partnership will implement the Enhanced Breast Cancer Detection (EBCD) protocol, which utilizes DeepHealth's AI technology to improve cancer detection rates by 21% [3] - OB/GYN Specialists will also integrate DeepHealth's AI-driven health informatics, which includes a cloud-based operating system and patient tracking services [4] Strategic Goals - The collaboration emphasizes a commitment to expanding breast health services and providing women with proactive screening options [5] - Both companies aim to make early detection more convenient, accurate, and accessible for patients [5]

Core Insights - DeepHealth, Inc. and ConcertAI's TeraRecon have announced a strategic collaboration to enhance imaging tools and radiology workflows through AI integration [1][2][4] - The partnership aims to create a seamless AI-enabled diagnostic experience for radiologists by integrating TeraRecon's advanced visualization technology into DeepHealth's cloud-native Operating System [1][3] - This collaboration is expected to improve diagnostic efficiency and patient care by providing radiologists with essential tools to manage increasing imaging volumes and maintain accuracy [2][5] Company Overview - DeepHealth is a wholly-owned subsidiary of RadNet, Inc., focusing on AI-powered health informatics to improve clinical outcomes in various health areas, including lung, breast, prostate, and brain health [10] - TeraRecon specializes in advanced radiological image visualizations and clinical AI decision augmentation solutions, enhancing the capabilities of medical imaging [9] - Both companies are exploring further integration of AI-driven imaging and workflow automation to enhance diagnostic tools and care delivery [6][8] Technology Integration - The integration of TeraRecon's advanced visualization capabilities with DeepHealth's OS and Diagnostic Suite is designed to enhance diagnostic accuracy and streamline workflows for radiologists [4][8] - DeepHealth's Diagnostic Suite™ will provide a unified AI-powered diagnostic workspace, improving collaboration and efficiency among radiology teams [3][8] - The collaboration will also explore the integration of DeepHealth's AI-powered cancer screening capabilities into TeraRecon's ecosystem, broadening access to essential diagnostic tools [5][8]